Assessing the Landscape of HER2+ Breast Cancer Treatment

Pharmacy Times Oncology Edition, April 2022, Volume 4, Issue 2

New therapies and combination regimens may allow a more tailored approach.

More than 2 million women worldwide received a diagnosis for breast cancer in 2020.1 Although breast cancer remains the second leading cause of cancer-related deaths among women in the United States, its early detection and improved treatment modalities have led to significantly increased survival rates.

Molecular testing, performed upon diagnosis to identify breast cancer subtype, provides insight into disease features and potential therapeutic targets. In general, breast cancer can be classified into 3 major subtypes: luminal, HER2 overexpressed, and triple negative.2

Found in approximately 30% of breast cancers, HER2 overexpression historically has been associated with more aggressive disease and poorer prognosis.3 To determine HER2 status, results of immunohis-tochemistry (IHC) staining are categorized as 0 or 1+ (negative), 2+ (uncertain), and 3+ (positive). When HER2 overexpression is detected with a result of IHC 3+, HER2 blockade becomes an effective treatment strategy. Management of early-stage breast cancer (eBC) involves a combination of surgery, radiation, and systemic treatment; however, the latter currently is the mainstay of treatment for metastatic breast cancer (mBC).

Monocloncal Antiboties

Following the introduction of anti-HER2 treatments to the market, survival rates for patients with HER2-positive (HER2+) breast cancer significantly improved. Trastuzumab (Herceptin; Genentech USA, Inc), a fully humanized monoclonal antibody, was introduced in 1998 as the first anti-HER2 agent.4 It binds the HER2 receptor to block cell proliferation and promotes antibody-dependent, cell-mediated cytotoxicity. Through these actions, it enhances the antitumor effect when given with cytotoxic chemotherapy in HER2-overexpressing breast cancer cells.5 It is given as an intravenous (IV) formulation over 30 to 90 minutes every 1 or 3 weeks or subcutaneously every 3 weeks, depending on disease stage and formulation used.6

Trastuzumab lowers the risk of relapse by 40% when given as adjuvant therapy for 1 year in eBC; it reduces the risk of death by 20% in mBC when combined with standard chemotherapy.3,7 Additionally, for more than 15 years, single-agent anti-HER2 blockade using trastuzumab-based chemotherapy served as the standard first-line approach for HER2+ mBC.

However, in 2015, results from the CLEOPATRA study (NCT00567190) demonstrated an overall survival (OS) improvement of almost 16 months when pertuzumab (Perjeta; Genentech USA, Inc) was added to the first-line trastuzumab-based chemotherapy regimen, establishing dual anti-HER2 blockade as the new standard of therapy.4

Pertuzumab is also a humanized monoclonal antibody, but it works by binding a different region of the HER2 receptor that enhances HER2 inhibition in overexpressing breast cancer cells when given with trastuzumab.

Trastuzumab is the backbone of anti-HER2 treatment, yet the risk for cardiac toxicity may limit its use in certain patients. The FDA issued a black box warning for cardiomyopathy because of a 4- to 6-fold increased risk of symptomatic cardiac adverse effects (AEs; eg, left ventricular cardiac dysfunction, arrhythmias, hyper- tension, cardiomyopathy, cardiac failure, cardiac death) observed in clinical trials.8 For this reason, regular cardiac monitoring must be performed during therapy and for 2 years following completion of therapy.6

Common challenges encountered with trastuzumab therapy include resistance and disease progression; the former is commonly noted in the mBC setting, and it typically develops within 1 year from the beginning of treatment.9 Because mBC is incurable, the disease eventually progresses in most patients on an initial trastuzumab-based therapy, and 40% to 50% of patients develop brain metastases. Anti-HER2 monoclonal antibodies typically are ineffective in treating central nervous system (CNS) progression because they cannot cross the blood-brain barrier (BBB). Despite resistance or progression, strong evidence supports continuing a trastuzumab-based regimen indefinitely.10-12

Consensus on the optimal therapeutic selection beyond the second-line setting is lacking. Ongoing research is underway to evaluate various strategies, such as novel therapeutics and new combination regimens, to optimize therapy sequencing and to enhance the prevention and treatment of CNS metastasis.

Tyrosine Kinase Inhibitors

Small molecule tyrosine kinase inhibitors (TKIs) that can penetrate the BBB are an attractive option for managing HER2+ mBC patients with brain metastases. Lapatinib (Tykerb; Novartis), one of the first TKIs studied in this setting, demonstrated synergistic activity when combined with anti-HER2 monoclonal antibodies.4 As a reversible inhibitor of both HER2 and EGFR receptors, lapatinib successfully inhibits the growth of HER2+ breast cancer cells and enhances anti-HER2 antibody-induced apoptosis. When lapatinib was given in combination with capecitabine (Xeloda; Genentech USA, Inc), fewer cases of CNS progression were observed.13

Dosing of lapatinib generally ranges from 1250 mg to 1500 mg taken orally once daily.14 The main AEs reported include diarrhea, palmar-plantar erythrodysesthesia, nausea, skin rash, vomiting, and fatigue. Current use of lapatinib is reserved beyond first-line treatment; it is given in combination with capecitabine.

Neratinib (Nerlynx; Puma Biotechnology, Inc) is another TKI approved for use in the HER2+ breast cancer setting. It is FDA approved for extended adjuvant treatment of early-stage disease following adjuvant trastuzumab-based treatment, as well as for use with capecitabine in the metastatic setting following 2 or more prior anti-HER2 therapies.15 Neratinib is administered orally at a typical maintenance dose of 240 mg once daily. Treatment is typically initiated with gradual dose escalation or loperamide prophylaxis to improve the drug’s tolerability, as diarrhea is the most common grade 3 or 4 toxicity seen with neratinib.

Tucatinib (Tukysa; Seagen Inc) given with trastuzumab and capecitabine is a preferred third-line regimen for patients with systemic and CNS progression. It gained preferential status based on findings that this combination improved 1-year progression-free survival (PFS) by more than 20% compared with a trastuzumab-capecitabine combination.16 This improvement was
even greater in patients with brain metastases who were given tucatinib-trastuzumab-capecitabine vs those given trastuzumab-capecitabine (24.9% vs 0%), suggesting that CNS disease control is enhanced when tucatinib is part of the regimen. Typical dosing of tucatinib is 300 mg orally twice daily.17 The main AEs observed in the tucatinib-combination group included diarrhea, palmarplantar erythrodysesthesia, nausea/vomiting, and fatigue.

Antibody-Drug Conjugates

Novel antibody-drug conjugates (ADCs) are gaining traction as a unique treatment option for HER2+ mBC. Ado-trastuzumab emtansine (T-DM1; Kadcyla; Genentech USA, Inc) is a trastuzumab conjugate that consists of trastuzumab covalently linked to the cytotoxic agent emtansine.4 The EMILIA trial (NCT00829166) compared the use of T-DM1 with lapatinib-capecitabine, finding that T-DM1 treatment resulted in significant improvements in PFS (median, 9.6 months vs 6.4 months, respectively) and an OS benefit (HR, 0.62; 95% CI, 0.48-0.81; P = .0005).18 T-DM1 also offered a favorable toxicity profile when compared with lapatinib-capecitabine, with lower rates of grade 3 and 4 AEs (41% vs 57%) and lower incidences of diarrhea, nausea/vomiting, and palmar-plantar erythrodysesthesia. Given the efficacy and relative tolerability of T-DM1, it is the preferred second-line regimen following trastuzumab plus pertuzumab with a taxane (docetaxel preferred). Administration is via IV infusion every 3 weeks.19

Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo Company, Limited), administered as an IV infusion every 3 weeks, is the only other trastuzumab- ADC conjugate currently on the market. In breast cancer, its use remains reserved for administration beyond the third-line setting because of the lack of
OS data.4 Several other second-generation ADCs (SYD985, XMT-1522, ARX788, DHES0815A) are being developed to replace T-DM1 and produce a more durable, potent effect.

Margetuximab-cmkb (Margenza; MacroGenics, Inc) used with chemotherapy (capecitabine, eribulin, gemcitabine, vinorelbine) gained FDA approval in 2020 as a third-line treatment option for HER2+ mBC based on a 1-month improvement in median PFS and a 6% increased objective response rate when compared with trastuzumab plus chemotherapy.20 The initial dose is administered via IV infusion over 120 minutes, followed by 30-minute infusions every 3 weeks thereafter.21

Investigational Agents

The bispecific, trifunctional antibody ertumaxomab (Rexomun; Fresenius Biotech GmbH) is still in phase 1 development, but it offers a new approach to cancer treatment.22 It works by targeting HER2 on cancer cells and triggers immune cells at the sites of metastases to form a tricell complex between tumor cell, T cell, and accessory cells. This complex then leverages natural immunologic mechanisms to initiate a humoral and cellular immune response to destroy HER2+ tumor cells.

Research is ongoing surrounding HER2-targeted vaccines. Early observations indicated that at early stages of disease, patients with cellular or humoral immune responses against HER2 had lower tumor development of HER2-overexpressing cells.4 An effective vaccine given in the eBC setting would reduce the need for frequent infusions or injections of standard treatment and help prevent disease recurrence.9 The main barrier to developing an effective vaccine at this point is immunologic tolerance against the HER2 antigen.

CDK4/6 inhibition is an emerging treatment option for HER2+ mBC. Given FDA approval and successful use of CDK4/6 inhibitors in the HER2-negative setting, these targeted agents may be beneficial in HER2+ mBC to block cell proliferation downstream of HER2.23 Additionally, these agents can cross the BBB and may be able to improve the prevention and treat- ment of HER2+ mBC brain metastases.

Currently, there are 3 CDK4/6 inhibitors on the market: abemaciclib (Verzenio; Lilly USA, LLC), ribociclib (Kisqali; Novartis Pharmaceuticals Corporation), and palbociclib (Ibrance; Pfizer Inc). All are orally administered, but ribociclib and palbociclib are taken on a cyclical basis (3 weeks on/1 week off), whereas abemaciclib is dosed continuously.24-26 The predominant toxicity experienced by patients on abemaciclib is diarrhea; corrected QT interval prolongation is primarily seen with ribociclib, and neutropenia is noted with palbociclib. Patient factors such as adherence, comorbidities, concomitant medications, and performance status must be considered when selecting one of these therapies for a patient.


As more data emerge, guidance on optimal treatment sequencing for HER2+ mBC may become available. Development of new therapies and combination regimens will improve patient outcomes and offer a more tailored approach to therapy. As enhanced treatment options emerge, patient preferences regarding cost, administration method, and overall therapy convenience may play a larger role in therapy selection.

Chelsey Lindner, PharmD, BCOP, is a clinical pharmacist at Shields Health Solutions.


  1. Facts & Figures 2021. American Cancer. 2021. Accessed Nov 18, 2021.
  2. Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929-2943.
  3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
  4. Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4:34. doi:10.1038/s41392-019-0069-2
  5. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26(4 suppl 12):60-70.
  6. Herceptin. Prescribing information. Genentech; 2021. Accessed January 12, 2022.
  7. Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration, and combination therapies. Breast. 2013;22(suppl 2):S152-S155. doi:10.1016/j.breast.2013.07.029
  8. Mohan N, Jian J, Dokmanovic M, Jin Wu W. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018;1(1):13-17. doi:10.1093/abt/tby003
  9. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. 2010;59(9):1295-1312. doi:10.1007/s00262-010-0869-2
  10. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25:3853-3858. doi:10.1200/JCO.2007.11.9776
  11. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006. doi:10.1200/JCO.2008.19.6618
  12. von Minckwitz G, Zeilinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol. 2008;26(suppl 15):1025.
  13. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-543. doi:10.1007/s10549-007-9885-0
  14. Tykerb. Prescribing information. Novartis Pharmaceuticals Corporation; 2021. Accessed November 18, 2021.
  15. Nerlynx. Prescribing information. Puma Biotechnology; 2021. Accessed January 12, 2022.
  16. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609. doi:10.1056/NEJMoa1914609
  17. Tukysa. Prescribing information. Seagen Inc.; 2020. Accessed January 12, 2022.
  18. Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791. doi:10.1056/NEJMoa1209124
  19. Kadcyla. Prescribing information. Genentech; 2020. Accessed November 18, 2021.
  20. Rugo HS, Im S, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573-584. doi:10.1001/jamaoncol.2020.7932
  21. Margenza. Prescribing information. MacroGenics; 2020. Accessed January 12, 2022.
  22. Haense N, Atmaca A, Pauligk C, et al. A phase I trial of the trifunctional anti HER2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016;16:420. doi:10.1186/s12885-016-2449-0
  23. O’Sullivan CC, Suman VJ, Goetz MP. The emerging role of CDK4/6i in HER2-positive breast cancer. Ther Adv Med Oncol. 2019;11:1758835919887665. doi:10.1177/1758835919887665
  24. Verzenio. Prescribing information. Eli Lilly and Company; 2021. Accessed November 18, 2021.
  25. Kisqali. Prescribing information. Novartis Pharmaceuticals Corporation; 2021. Accessed November 18, 2021.
  26. Ibrance. Prescribing information. Pfizer Labs; 2019. Accessed January 12, 2022.